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Abstract
Background: Diagnosing extrapulmonary tuberculosis (EPTB) is challenging and many patients are initiated on
empirical anti-TB treatment without a laboratory confirmed diagnosis. Monitoring treatment response is thus
important to ensure correct diagnosis and proper disease management. The definition of satisfactory response to
treatment in EPTB remains unclear. The objectives of this study were to describe the clinical presentation of EPTB
and the effect of treatment on clinical parameters. Further, to assess if simple clinical parameters, without laboratory
data, could evaluate treatment response.
Methods: Prospective cohort study of presumptive EPTB patients at Mnazi Mmoja Hospital, Zanzibar. By using a
composite reference standard, patients were categorized as TB or non-TB cases. The TB patients were followed
during anti-TB treatment.
Results: There were 64 TB and 62 non-TB cases. The frequency of symptoms at baseline were comparable in TB
and non-TB patients, with lymphadenitis and pleuritis as the most common manifestations. Among TB cases, there
was a trend towards regression of lymphadenopathy after 2 months, and at treatment completion 24/28 (86%)
cases showed full regression. Weight gain ≥5% was reported in 36/49 (73%) of the TB patients at 2 months and in
38/46 (83%) at treatment completion. After 2 months of treatment, a combination of clinical parameters;
improvement of symptoms (50/50), ≥5% weight gain (36/49) and regression of physical signs (45/49) correlated
with the treatment response.
Conclusions: An algorithm including only simple clinical parameters could be used as an easy tool to assess
treatment responses in low-resource settings. However, this needs to be tested on a larger sample size.
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Background
Globally, extrapulmonary tuberculosis (EPTB) accounts
for 15% of the notified incident tuberculosis (TB) cases
[1]. Laboratory confirmation of EPTB is challenging due
to the paucibacillary nature of disease and limited
resources in high-TB endemic settings. The diagnosis is
therefore often made only on medical history and clin-
ical signs and many patients are started on empirical
anti-TB treatment. It is thus important to monitor
response to treatment to ensure diagnosis and appropri-
ate disease management. Monitoring response to treat-
ment in EPTB is challenging and clinical assessment is
generally recommended [2]. However, the definition of
satisfactory clinical response to treatment among the
various forms of EPTB remains unclear. Earlier studies
have suggested a combination of clinical and laboratory
criteria for evaluating response to treatment [3, 4].
Repeated invasive procedures or measurement of inflam-
matory markers are often incorporated in the definition
of treatment response [4]. In low-resource settings with
limited capacity for laboratory investigations and
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invasive procedures, it would be useful to assess
response to treatment in EPTB by using simple clinical
criteria.
In Zanzibar the estimated prevalence of bacteriologic-
ally confirmed pulmonary TB (PTB) among the adult
population is 124/100000 [5]. In 2015, EPTB accounted
for 24% of the notified TB cases [6]. In contrast to PTB,
the EPTB patients are not followed systematically by the
TB programme during anti-TB treatment. Symptoms
and signs are often not documented in the TB records
and the only information available is “treatment com-
pleted”, which does not always correspond to successful
remission.
The objectives of this study were to describe the
clinical presentation of EPTB among patients presenting
at Mnazi Mmoja Hospital (MMH), Zanzibar, and to
describe the effect of anti-TB treatment on clinical
parameters. Further, to assess if simple clinical parame-
ters, without laboratory support, could be used to
reliably evaluate treatment response.
Methods
Study setting and population
This prospective cohort study was nested in a larger
project at MMH [7], the main referral hospital in
Zanzibar. Children and adults presenting with symptoms
suggestive of EPTB were enrolled from in- and outpatient
departments for a period of thirteen months starting 1st
of August 2014. Patients were excluded if a specimen
from the presumptive site of infection was not sent for
laboratory investigations, if they did not give consent or
had received anti-TB treatment during the previous year.
Data collection
A medical history was obtained from the patients using
their local language, Swahili, and a physical examination
was performed at the time of inclusion and at follow-up
visits after the intensive phase of anti-TB treatment at 2
months (median 71 days, 5–95 percentile 55–109 days)
and at the end of treatment (median 175 days, 5–95
percentile 145–244 days). At inclusion, a pretested
semi-structured questionnaire was used [7]. At the
follow-up visits, clinical assessment was done without a
standard questionnaire. Improvement of symptoms;
cough, fever, appetite, fatigue, local symptoms and
general condition reported by the patient and assessed
by clinician, and results from the physical examination
were registered in the patient’s study folder. Patients
who were not started on anti-TB therapy were followed
until a diagnosis was established or until recovery.
Clinical investigation
Enlarged lymph nodes were measured by the size of the
long axis of the largest swelling using a measuring tape,
if not available, an eye estimate was used. Any change
during anti-TB treatment in the size of nodes, appear-
ance of new nodes, formation of fistulae and/or ab-
scesses were recorded. Size of the lymph nodes was
designated to one of four categories; not palpable
(palpable lymph nodes < 1 cm was also included in this
group), ≤2 cm, > 2–4 cm or > 4 cm. Residual lymphaden-
opathy after treatment was defined as palpable lymph
nodes > 1 cm. Pleural or peritoneal effusions were evalu-
ated clinically and by X-ray and ultrasound when avail-
able. All patients were weighed, and weight change was
recorded in kilograms (kg) and as percentage change in
weight at two intervals; 1) between treatment onset and
2months of treatment, and 2) between treatment onset
and end of treatment.
Laboratory investigations
Acid-fast bacilli (AFB) microscopy, Mycobacterium
tuberculosis (Mtb) culture, GeneXpert® MTB/RIF (Xpert)
assay, and cytological/histological evaluation were
performed on extrapulmonary specimens. In addition,
other laboratory investigations such as bacteriological
culture and Gram staining, and protein quantification
and white cell count in effusions, were performed if
available. CD4 cell counts and human immunodeficiency
virus (HIV) ribonucleic acid levels were not available for
the HIV positive patients.
Composite reference standard for categorization of
patients
A composite reference standard (CRS) was used to
categorize the study participants as “confirmed TB
cases” (positive Mtb culture and/or Mtb detected by the
Xpert assay), “probable TB cases” (clinical presumptive
EPTB and either response to anti-TB treatment or
bacteriologically confirmed PTB, and one of the follow-
ing; AFB on Ziehl-Neelsen stain of extrapulmonary
specimen or cytology/histology consistent with TB or
lymphocytosis on fluid cytology or radiological findings
suggestive of EPTB), “possible TB cases” (clinical
presumptive EPTB and one of the following; AFB on
Ziehl-Neelsen stain of extrapulmonary specimen or
cytology/histology consistent with TB or lymphocytosis
on fluid cytology or radiological findings suggestive of
EPTB or response to anti-TB treatment) and “non-TB
cases” (negative Mtb culture and/or Mtb not detected by
the Xpert assay and one of the following; improvement
without anti-TB treatment or cytology/histology con-
cluded other diagnosis than TB or alternative diagnosis
concluded by the local clinician or non-response to
anti-TB treatment) [7]. Patients unable to be categorized
by the CRS were termed “uncategorized” and excluded
from further analyses [7].
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Statistical analysis
Chi-square test was used in the analysis of categorical
variables and Mann-Whitney U test and Kruskal-Wallis
test for group-wise comparison of continuous variables.
The general significance level was set to 0.05. Bonferroni
correction was used to adjust for multiple testing effects
leading to a marginal level of 0.0071 for symptoms (7
tests), 0.01 for presumptive TB lymphadenitis (5 tests)
and 0.017 for weight gain (3 tests). Data were analysed
using IBM SPSS Statistics for Windows, version 24
(Armonk, NY, USA), and graphics were created using
Matlab 9.0 (Natick, MA, USA).
Results
Study participants
A total of 132 patients were enrolled and based on
the CRS categorized as TB (confirmed, n = 12; prob-
able, n = 34; possible, n = 18) and non-TB (n = 62)
cases, while 6 patients were uncategorized and excluded
from further analyses. Baseline sociodemographic and
clinical characteristics are presented in Table 1.
Among the 64 TB cases, 10 (16%) died before first
follow-up, and 2 (3%) were lost-to-follow. Thus, 52 TB
patients were followed during treatment. Forty patients
received standard first-line anti-TB regimen (isoniazid
(H), rifampicin (R), pyrazinamide (Z) and ethambutol
(E), 2HRZE/4HR), 2 patients an extended standard
first-line regimen, 7 children received a regimen
without ethambutol (2HRZ/4HR), whereas 3 patients
received a retreatment regimen containing first-line
drugs including streptomycin (S) (2HRZES/1HRZE/
5HRE). An overall clinical improvement was noted in
all 52 patients after 2 months of treatment (one
patient only assessed after 5 months), but a transient
paradoxical reaction with increase in lymphadenop-
athy was observed in 2 HIV positive patients. Empir-
ical anti-TB treatment was initiated in 12/62 (19%)
non-TB patients. Among these, 5/12 patients received
a malignant diagnosis, 5/12 cases showed no response
to treatment and were further investigated for an
alternative diagnosis, 1/12 patients showed clinical
improvement before starting anti-TB treatment and 1/
12 cases (presumptive TB meningitis) only received
anti-TB treatment for 2 weeks due to side-effects and
improved without anti-TB therapy.
TB and non-TB patients present with similar symptoms
Table 2 presents the distribution of symptoms among
TB and non-TB cases according to site of infection, age
and HIV status. There was no significant difference in
the frequency or type of constitutional symptoms when
comparing TB with non-TB patients. All patients
reported local symptoms from the site of infection.
Among the TB cases, patients with lymphadenitis
reported less frequently constitutional symptoms as
compared to patients with pleuritis and other sites of
infection. Paediatric patients described less constitu-
tional symptoms compared to adults. Weight loss,
reduced appetite or fatigue were reported more often in
adults. Constitutional symptoms were more frequent in
HIV positive patients.
Table 1 Characteristics of the study participants
Total Lymphadenitis Pleuritis Other sites of infectiona
n = 126 n = 67 n = 31 n = 28
TB Non-TB TB Non-TB TB Non-TB
Characteristics n = 34 n = 33 n = 20 n = 11 n = 10 n = 18
Female, n (%) 56 (44%) 17 (50%) 14 (42%) 7 (35%) 5 (45%) 5 (50%) 8 (44%)
Age, years, median [IQR] 27 [8–41] 27 [7–38] 13 [7–49] 32 [23–50] 20 [6–41] 27 [19–34] 40 [26–50]
Children (< 15 years), n (%) 41 (33%) 11 (32%) 18 (55%) 3 (15%) 4 (36%) 2 (20%) 3 (17%)
HIV status, n (%)
HIV positive 20 (16%) 7 (21%) 2 (6%) 5 (25%) 0 (−) 2 (20%) 4 (22%)
HIV negative 74 (59%) 25 (74%) 10 (30%) 15 (75%) 6 (55%) 6 (60%) 12 (67%)
Unknown 32 (25%) 2 (6%) 21 (64%) 0 (−) 5 (45%) 2 (20%) 2 (11%)
Comorbidities, n (%)
Diabetes 4 (3%) 0 (−) 1 (3%) 1 (5%) 1 (9%) 1 (10%) 0 (−)
Heart disease/HT 12 (10%) 2 (6%) 3 (9%) 0 (−) 2 (18%) 1 (10%) 4 (24%)
COPD/Asthma 7 (6%) 3 (9%) 2 (6%) 0 (−) 1 (9%) 1 (10%) 0 (−)
Outpatient, n (%) 76 (60%) 32 (94%) 32 (97%) 7 (35%) 0 (−) 3 (30%) 2 (11%)
Abbreviations: TB tuberculosis, IQR interquartile range, HIV human immunodeficiency virus, HT hypertension, COPD chronic obstructive pulmonary disease
a TB cases: peritonitis (n = 6), meningitis (n = 2), pericarditis (n = 1), spondylitis (n = 1); non-TB cases: peritonitis (n = 10), meningitis (n = 6), mastitis (n = 1),
osteomyelitis (n = 1)
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Findings in presumptive TB lymphadenitis
There was no statistically significant difference in the
site or symmetry of lymph node involvement between
TB and non-TB patients (Table 3). Still, a higher propor-
tion of larger lymph nodes > 4 cm, matted or painful
nodes and discharge/fistulas were seen in TB patients
compared to non-TB patients.
There was a significant regression in lymph node size
with anti-TB treatment, as shown in Fig. 1. During
treatment enlargement of nodes, new fistulae or fresh
abscesses were reported in 5 (2 HIV positive) patients.
However, overall reduction in lymph node size was seen
as an indicator for treatment response among TB
patients.









appetite≥1 symptoms ≥3 symptoms
Diagnosis
TB 64 50 (78%) 23 (36%) 33 (52%) 36 (57%) 21 (33%) 16 (26%) 20 (32%)
Non-TB 62 42 (68%) 22 (35%) 26 (42%) 25 (42%) 18 (29%) 24 (39%) 18 (30%)
P valuec .189 .958 .279 .086 .604 .109 .741
TB cases
Confirmed TB 12 9 (75%) 3 (25%) 6 (50%) 6 (50%) 3 (25%) 3 (27%) 4 (33%)
Probable TB 34 28 (82%) 16 (47%) 21 (62%) 23 (70%) 12 (35%) 8 (24%) 13 (38%)
Possible TB 18 13 (72%) 4 (22%) 6 (33%) 7 (39%) 6 (35%) 5 (29%) 3 (19%)
Site
Lymphadenitis
TB 34 22 (65%) 7 (21%) 14 (41%) 15 (45%) 7 (21%) 2 (6%) 5 (15%)
Non-TB 33 15 (45%) 6 (18%) 9 (27%) 8 (25%) 4 (12%) 5 (16%) 7 (21%)
Pleuritis
TB 20 20 (100%) 12 (60%) 13 (65%) 16 (80%) 11 (55%) 9 (47%) 12 (63%)
Non-TB 11 11 (100%) 6 (55%) 7 (64%) 6 (55%) 7 (64%) 8 (73%) 4 (40%)
Other sites
TB 10 8 (80%) 4 (40%) 6 (60%) 5 (50%) 3 (33%) 5 (50%) 3 (30%)
Non-TB 18 16 (89%) 10 (56%) 10 (56%) 11 (65%) 7 (39%) 11 (61%) 7 (39%)
Age
Children
TB 16 12 (75%) 2 (13%) 8 (50%) 5 (31%) 6 (38%) 1 (6%) 0 (−)
Non-TB 25 14 (56%) 6 (24%) 8 (32%) 6 (25%) 6 (24%) 7 (28%) 6 (25%)
Adults
TB 48 38 (79%) 21 (44%) 25 (52%) 31 (66%) 15 (32%) 15 (33%) 20 (43%)
Non-TB 37 28 (76%) 16 (43%) 18 (49%) 19 (53%) 12 (32%) 17 (47%) 12 (32%)
HIV statusd
HIV positive
TB 14 13 (93%) 6 (43%) 8 (57%) 8 (62%) 5 (38%) 6 (46%) 6 (43%)
Non-TB 6 6 (100%) 4 (67%) 6 (100%) 3 (60%) 1 (17%) 4 (67%) 3 (50%)
HIV negative
TB 46 33 (72%) 16 (35%) 21 (46%) 27 (59%) 14 (30%) 9 (20%) 14 (32%)
Non-TB 28 20 (71%) 10 (36%) 11 (39%) 15 (54%) 8 (29%) 11 (39%) 8 (29%)
Abbreviations: TB tuberculosis, HIV human immunodeficiency virus
a Patients with missing values excluded
b The following were included as constitutional symptoms; fever, weight loss, night sweats, fatigue, loss of appetite. ≥1 and ≥ 3 refers to number of patients
reporting one or more or three or more symptoms respectively
cP value < 0. 0071 (0.05/7) considered statistically significant
d Patients with unknown HIV status excluded
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Regression of pleural and peritoneal effusion during anti-
TB treatment
Among the 20 TB pleuritis cases, any regression of effu-
sion was assessed by chest x-ray in 15 patients after 2
months and in 13 patients at treatment completion.
Regression was noted in 14 (93%) and 13 (100%),
respectively. Only 3/6 (50%) with abdominal TB were
evaluated, and partial regression of peritoneal effusion
was seen at 2 months and full regression at the end of
treatment, as assessed by ultrasound.
Weight gain as indicator for treatment efficacy
Weight change during anti-TB treatment was recorded
according to age, site of infection and HIV status (Fig. 2).
After 2 months of treatment, 36/49 (73%) of the patients
had ≥5% weight gain and 18/49 (37%) had ≥10% weight
gain. At treatment completion, 38/46 (83%) of the cases
had ≥5% and 26/46 (57%) ≥10% weight gain. Overall, the
median weight gain at 2 months of treatment was 2.9
kg (interquartile range (IQR), 1.4–5.1 kg) and the me-
dian percentage weight gain 6.7% (IQR, 4.6–13.4%).
After completion of treatment, the overall median
weight gain was 4.0 kg (IQR, 2.2–7.5 kg) and 12.9%
(IQR, 7.2–19.7%). The paediatric cases had a higher
median percentage weight gain compared to the adult
patients both at 2 months (11.1% vs 6.2%) and end of
treatment (17.9% vs 9.5%), but the differences were
not statistically significant. A weight gain ≥15% was
described in 71% of the paediatric TB cases at treat-
ment completion. In all HIV positive cases (n = 5)
≥5% weight gain was seen after treatment completion,
and 4/5 patients had a weight gain ≥15%. There was
no statistically significant difference in weight gain
according to site of disease.
Table 3 Findings in presumptive TB lymphadenitis at the time of inclusion, n (%)
Diagnosis
Total TB Non-TB P valuea
Characteristics n = 67 n = 34 n = 33
Localization .549b
Unilateral 40 (60%) 22 (65%) 18 (55%)
Bilateral/generalized 27 (40%) 12 (35%) 15 (45%)
Only cervical 50 (75%)
Unilateral 17 (50%) 14 (42%)
Bilateral 9 (26%) 10 (30%)
Only axillary 6 (9%)
Unilateral 3 (9%) 3 (9%)
Bilateral 0 (−) 0 (−)
Only inguinal 2 (3%)
Unilateral 0 (−) 1 (3%)
Bilateral 0 (−) 1 (3%)
Cervical and axillary 6 (9%)
Unilateral 2 (6%) 0 (−)
Bilateral 1 (3%) 2 (6%)
Cervical bilateral and axilla unilateral 1 (3%) 0 (−)
Generalized 3 (4%) 1 (3%) 2 (6%)
Size of largest lymph nodec .031
≤ 2 cm 9 (13%) 1 (3%) 8 (24%)
> 2–4 cm 25 (37%) 13 (38%) 12 (36%)
> 4 cm 33 (49%) 20 (59%) 13 (39%)
Matted nodes 38 (57%) 24 (71%) 14 (42%) .020
Painful 9 (13%) 7 (21%) 2 (6%) .081
Discharge/fistula 7 (10%) 6 (18%) 1 (3%) .051
Abbreviation: TB tuberculosis
aP value < 0. 01 (0.05/5) considered statistically significant
b Test for different risk for unilateral vs. bilateral/generalized localization in TB and Non-TB group
c Long axis of largest lymph node swelling
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Combination of clinical parameters for assessment of
treatment outcome
Among the patients starting anti-TB treatment, a com-
bination of the following three clinical parameters were
assessed retrospectively; 1) Improvement of reported
symptoms; 2) Weight gain (any weight gain or ≥ 5%
gain); 3) Regression of lymph node swelling or pleural or
peritoneal effusion or other local findings, during and
after treatment compared to baseline. If a weight gain
≥5% was used, all TB cases, except one, had ≥2 parame-
ters after 2 months of treatment, while non-TB cases
fulfilled only 0 or 1 parameter (Fig. 3).
Discussion
In this study, we describe the clinical presentation of
various forms of EPTB and changes in clinical parame-
ters during the course of anti-TB treatment. Our results
show that presenting signs and symptoms alone could
not differentiate TB and non-TB cases among presump-
tive EPTB cases. There was regression in clinical signs in
TB cases during treatment, and we suggest that a com-
bination of 2–3 clinical parameters could predict good
response early (2 months) in the treatment. These find-
ings imply that in low-resource settings where anti-TB
treatment is often started on clinical assumption,
Fig. 1 Time series plot illustrating the regression of lymphadenopathy during anti-TB treatment. The lymph node size (long axis of largest
swelling) is presented at baseline, after 2 months of treatment and at treatment completion according to TB category (confirmed, probable and
possible TB cases) and age. Each patient is represented by an individual line. At baseline, all, except one case, had lymph node enlargement
> 2 cm. At 2 months, there was a trend in regression of lymph node swellings, and at treatment completion, 4 (14%) cases had residual
lymphadenopathy. The patients with residual lymphadenopathy were all confirmed TB cases. Abbreviation: TB, tuberculosis
Fig. 2 Boxplots showing the weight change at 2 months of anti-TB treatment and at treatment completion. Left boxplot: weight change in kg
between treatment onset and 2months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV
status and age. Right boxplot: weight change as percentage change in weight between treatment onset and 2months of treatment and
between treatment onset and end of treatment according to site of TB infection, HIV status and age. Abbreviations: TB, tuberculosis; HIV, human
immunodeficiency virus
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unnecessary over-treatment can be reduced by system-
atic clinical monitoring of responses early during
treatment.
Improvement in symptoms can be assessed by a symp-
toms count ratio [3], or self-rated health using the
EQ-5D 3 level version [8]. Overall clinical improvement
or performance status can be assessed by the health care
worker using standardised systems, like the Karnofsky
performance score [3, 9]. However, clinically relevant
cut-off points for symptoms count ratio, improvement of
self-rated health, performance scores and other clinical
parameters such as weight gain need to be established in
EPTB patients.
Weight gain is an easy, inexpensive parameter for
assessing treatment response. Earlier studies, predomin-
antly among PTB patients, have suggested an association
with weight gain and successful treatment outcome [10],
whereas lesser weight gain or weight loss were associ-
ated with poor outcome [10–12] or relapse [13]. Only a
few studies have evaluated weight gain as a marker of
treatment response in EPTB patients [3, 10, 12]. In our
cohort of TB cases with successful treatment outcome,
≥5% weight gain was recorded in 73 and 83% of the
cases at 2 months and at treatment completion.
Regression of lymphadenopathy could also be a
reliable parameter for assessment of response to treat-
ment, but appearance of newly enlarged nodes, enlarge-
ment of existing nodes, formation of new fistulae and
abscesses during and after treatment [14, 15] can
complicate the evaluation. Paradoxical reactions during
anti-TB treatment [16], are described to occur quite
frequently in TB/HIV co-infected patients [17, 18]. In a
meta-analysis, the frequency was estimated to be 15.7%
among patients treated for active TB and newly
commencing antiretroviral therapy [16, 19]. Further,
paradoxical reactions are reported to be relatively com-
mon in HIV negative EPTB patients [20–25]. Therefore,
a single clinical parameter may not be enough, and a
combination of parameters will be better to differentiate
responders from non-responders.
The failure to treatment response could indicate not
just alternative diagnoses but also poor compliance,
paradoxical reactions or drug resistance in TB cases.
These can be difficult to differentiate using only simple
clinical parameters. Still, such criteria, incorporated
systematically in the follow-up of TB patients, such as in
TB registers or treatment cards, can be valuable and
assist the health care provider in detecting patients who
need clinical reassessment.
Current practice in the TB programme (in
Zanzibar) does not detect EPTB patients with poor
clinical response. The TB register and treatment cards
document treatment completion as the only outcome
for EPTB which is based only on the intake of drugs
without concurrent record of clinical parameters. The
combination of clinical parameters described in this
study could be developed into an assessment tool,
which can be attached to the patients TB treatment
cards. However, the study sample is small, and the
findings need to be validated on a larger number of
patients. This simple tool has the potential to detect
non-responders early at 2 months and standardize
follow-ups. Early detection of non-responders would
save costs, reduce morbidity due to side-effects, and
further minimise the undue delay of alternative
diagnoses.
Fig. 3 Clinical parameters at 2 months of treatment for assessment of treatment outcome. Left figure: Shows the number of patients having each
clinical parameter. 1 – improvement of reported symptoms such as coughing, fever, appetite, fatigue and general condition. 2a – any weight
gain compared to baseline; 2b - ≥5% weight gain compared to baseline; 3 - regression of objective findings. Right figure: Shows the number of
patients having the sum of clinical parameters. Abbreviation: TB, tuberculosis
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The study has some limitations. Single centre study
and the small sample size limits the generalisability of
the results and sub-group analysis. There are few
patients included with presumptive neurological or bone
TB, and none with presumptive genital TB, urinary tract
TB or other forms of abdominal TB besides peritoneal
TB. Therefore, the results may not apply to all patients
presenting with presumptive EPTB in Zanzibar. The
possible TB cases were defined by clinically suspected
EPTB and overall response to treatment. This does not
provide an accurate diagnosis, as some of the patients
may have other infections responding to anti-TB treat-
ment. There was also a limited capacity to perform in-
vestigations to diagnose other infections and for the HIV
patients CD4 counts and viremia were not known. The
lack of standardized questionnaire and clinical registra-
tion during follow-up and standardized measurements
of lymph node size may have influenced the results.
Conclusions
Clinical presentation alone cannot reliably diagnose
EPTB, and empirical anti-TB treatment leads to
over-treatment. A combination of simple clinical param-
eters could be used as an easy tool to assess treatment
responses and thus improve patient management in
low-resource settings. More and larger studies are
needed for further evaluation and validation of these
simple clinical parameters.
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